Experts unpack key melanoma data shared during the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
During the 2026 American Society of Clinical Oncoloy Annual Meeting, OncLive® connected with experts to highlight impactful findings in melanoma and explore their potential clinical relevance. Find their insights below.
The combination of darovasertib and crizotinib (Xalkori) led to a clinically meaningful and statistically significant improvement in progression-free survival (PFS) vs investigator’s choice of therapy in patients with...
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.
An interim phase 1/2 trial update found that DB107-RRV plus DB107-FC could be given in combination with radiation in newly diagnosed high-grade glioma.